Please login to the form below

Not currently logged in
Email:
Password:

beloranib

This page shows the latest beloranib news and features for those working in and with pharma, biotech and healthcare.

Second patient death in Zafgen's obesity drug trial

A second patient enrolled in a phase III trial of Zafgen's obesity drug candidate beloranib has died, placing the future of the programme in doubt. ... Analysts suggested that the toxicity concern could give beloranib a tough time getting through

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Genetic Digital

We help healthcare, pharma & medical device organisations use web and mobile technologies to effectively connect patients and healthcare professionals....

Latest intelligence

Solaris Health looks at the gene therapy revolution
Gene therapies are bringing new hope for many people with diseases caused by genetic disorders...
PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...

Infographics